View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Heineken Holding N.V. reports transactions under its current share buy...

Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 9 March 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026. From 2 March 2026 up to and including 6 March 2026 a total of 73,013 shares were repurchased on exchange at an average price of € 69.40. Up to and...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Intron Health - AI Impact on Pharma - Thematic (20pgs) - Winners/Loser...

Our Big Pharma AI thesis is the result of ~25 interviews with industry execs & >100hrs of research. We show ~10% of OPEX could be saved by AI within a few years & conclude the recent sector rally is wholly justified & could run further. We assess the winners & losers from AI adoption and discuss in detail some of the short, mid & long-term consequences. We evaluate the various AI use cases and quantify the potential benefit they may have. We break down SG&A & R&D activities & show where AI is im...

Legrand SA: 1 director

A director at Legrand SA bought 800 shares at 143.240EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Press Release:  Sanofi’s Board of Directors proposes the appointment o...

Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress.  Patrick Kron, independent director and Chairman of the Nomination,...

 PRESS RELEASE

Communiqué de presse : Le Conseil d’administration de Sanofi propose l...

Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante   Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante  Paris, le 5 mars 2026. Le Conseil d’administration de Sanofi a décidé de proposer, dans le cadre de la prochaine Assemblée générale des actionnaires prévue le 29 avril 2026, la nomination de Christel Heydemann en qualité d’administratrice indépendante et le renouvellement des mandats de Christophe Babule et Jean-P...

Konrad Zomer
  • Konrad Zomer

Solvay SA: 1 director

A director at Solvay SA bought 820 shares at 26.500EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

 PRESS RELEASE

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

 PRESS RELEASE

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

 PRESS RELEASE

Notifications de participation par The Goldman Sachs Group

Notifications de participation par The Goldman Sachs Group Communiqué de presse                                                                 Information réglementée   Bruxelles, le 4 mars 2026 - 17h45 CET  Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), The Goldman Sachs Group, Inc a envoyé récemment à Solvay les notifications de transparence suivantes. Voici un résumé des notifications:  Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total  18 février 2026  ...

 PRESS RELEASE

Participation notifications by The Goldman Sachs Group

Participation notifications by The Goldman Sachs Group Press release                                                                  Regulated information  Brussels, March 4, 2026, 17:45 CET  In line with Belgian transparency legislation (Law of May 2, 2007), The Goldman Sachs Group, Inc recently sent to Solvay the following transparency notifications. Here is a summary of the notifications:  Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotal February 18, 2026 0.09% 7.55% 7.64%February 24, 20260.28%7.42%7.7...

 PRESS RELEASE

Participatiemeldingen van The Goldman Sachs Group

Participatiemeldingen van The Goldman Sachs Group Persbericht                                                                 Gereglementeerde informatie  Brussel, 4 maart 2026 - 17u45 CET  In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft The Goldman Sachs Group, Inc onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd. Hier is een samenvatting van de bewegingen:  Datum waarop de drempel werd overschreden Stemrechten Aan stemrechten gelijkgestelde financiële instrumenten Totaal  18 februari 2026  0...

Delphine Brault ... (+6)
  • Delphine Brault
  • Emira Sagaama
  • Juan Ros-Padilla
  • Luis de Toledo Heras
  • Marc Lavaud
  • Nathan Mietlicki
Delphine Brault ... (+6)
  • Delphine Brault
  • Emira Sagaama
  • Juan Ros-Padilla
  • Luis de Toledo Heras
  • Marc Lavaud
  • Nathan Mietlicki
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch